Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”), founded in 1996, is a subsidiary of Changchun High-Tech Industries (Group) Co., Ltd (stock code 000661). Its administrative …

At present, GenSci has more than 16 projects in the preclinical stage, and 8 projects are undergoing clinical stage. Therapeutic fields include growth and development, assisted …

GenSci is China's “demonstrationcenter for quality control of genetically engineered pharmaceuticals” and “the national incubation site of novel genetically engineered medicines.” …

Established in 1996, Changchun GeneScience Pharmaceutical Co., Ltd. (hereinafter referred to as ‘‘GenSci’) is one of the holding subsidiaries of Changchun High-tech (SZSE 000661)

Established in 1996, Changchun GeneScience Pharmaceutical Co., Ltd. (hereinafter referred to as ‘‘GenSci’) is one of the holding subsidiaries of Changchun High-tech (SZSE 000661)

GenSci059 was granted for clinical trial license by NMPA in September 2020 and Study May Proceed by US FDA in December 2020. It is deemed a milestone marked GenSci’s R&D …

Established in 1996, Changchun GeneScience Pharmaceutical Co., Ltd. (hereinafter referred to as ‘‘GenSci’) is one of the holding subsidiaries of Changchun High-tech (SZSE 000661)

Sep 10, 2021 · On December 18, 2020, Beijing time, GenSci’s Gentulizumab R&D project was approved by the US FDA for clinical trials, which means that this innovative therapy will soon …

Sep 10, 2021 · On December 18, 2020, Beijing time, GenSci’s Gentulizumab R&D project was approved by the US FDA for clinical trials, which means that this innovative therapy will soon …

Sep 10, 2021 · Established in 1996, Changchun GeneScience Pharmaceutical Co., Ltd. (hereinafter referred to as ‘‘GenSci’) is one of the holding subsidiaries of Changchun High-tech …